Fatal hepatic necrosis following imatinib mesylate therapy.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Blood

• Publication date

  2003-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2003-07-2323PMID 14568907
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• Imatinib mesylate (GleevecTM) reduces phlebotomy requirements in polycythemia vera

  2003cited by this paper
• Improving immune reconstitution while preventing graft-versus-host disease in allogeneic stem cell transplantation.

  2002cited by this paper
• Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis

  2002cited by this paper
• End points in cancer clinical trials and the drug approval process.

  2002cited by this paper
• Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

  2002cited by this paper
• Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

  2002cited by this paper
• Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

  2002cited by this paper
• Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

  2002cited by this paper
• Use of transjugular intrahepatic portosystemic shunt as a bridge to transplantation in fulminant hepatic failure due to Budd-Chiari syndrome.

  1997cited by this paper
• Chronic myelomonocytic leukemia transformation in polycythemia vera.

  1991cited by this paper
• Chronic myelomonocytic leukemia transformation in polycythemia vera.

  1991cited by this paper
• Budd-chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases

  1989cited by this paper
• The Budd-Chiari syndrome. Treatment by mesenteric-systemic venous shunts.

  1983cited by this paper
• Polycythemia vera with myelofibrosis and myeloid metaplasia. Acute hepatic failure following splenectomy.

  1980cited by this paper

• Liver Pathology Related to Onco-Therapeutic Agents.

  2023cites this paper
• Acute fulminant hepatitis related to the use of dasatinib: first case report.

  2022cites this paper
• Antioxidant-Based Preventive Effect of Phytochemicals on Anticancer Drug-Induced Hepatotoxicity

  2022cites this paper
• Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines.

  2022cites this paper
• Hepatotoxicity of FDA-approved small molecule kinase inhibitors

  2020cites this paper
• Histological changes of the rat liver after administration of imatinib mesylate:an experimental study

  2019cites this paper
• Update on the management of chronic myeloid leukemia: current best practice and future directions

  2019cites this paper
• Drug-induced liver injury

  2019cites this paper
• Severe liver toxicity in a chronic myeloid leukemia patient probably induced by a drug interaction between imatinib and sertraline

  2019cites this paper
• Сase Report of Acute Toxic Imatinib-induced Hepatitis in a Patient with Chronic Myeloid Leukemia, Sulfa Allergy, and Rheumatoid Arthritis

  2018cites this paper
• Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report

  2018cites this paper
• Drug-Induced Liver Injury—Perspectives from Pathology

  2018cites this paper
• European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

  2016cites this paper
• A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor

  2016cites this paper
• Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.

  2016cites this paper
• Kinase inhibitors and monoclonal antibodies in oncology: clinical implications

  2016cites this paper
• Drug-Induced Liver Injury.

  2015cites this paper
• Early onset imatinib mesylate-induced hepatotoxicity in a patient with gastrointestinal stromal tumors.

  2014cites this paper
• Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives

  2013cites this paper
• Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.

  2013cites this paper
• Tumor lysis syndrome soon after treatment with hydroxyurea followed by nilotinib in two patients with chronic-phase chronic myelogenous leukemia

  2013cites this paper
• Supervivencia tras trasplante hepático por fallo hepático agudo debido a imatinib: a propósito de un caso

  2012cites this paper
• Hepatotoxicity associated with lapatinib in an experimental rat model.

  2012cites this paper
• Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management

  2012cites this paper
• Chapter 25 – Drug-Induced Liver Injury

  2012cites this paper
• [Survival following liver transplant due to imatinib-induced acute liver failure: a case study].

  2012cites this paper
• disorders Imatinib targets other than bcr/abl and their clinical relevance in myeloid

  2011cites this paper
• Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

  2011cites this paper
• [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].

  2011cites this paper
• Imatinib-induced subclinical liver injury: histological changes of non-tumorous hepatic parenchyma

  2011influential citation
• Toksyczne uszkodzenie wątroby w przebiegu leczenia imatynibem chorych z przewlekłą białaczką szpikową Imatinib-induced toxic liver failure in patients with chronic myeloid leukemia

  2010cites this paper
• Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors

  2010influential citation
• Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase

  2010cites this paper
• Histopathological study of the hepatic and renal toxicity associated with the co-administration of imatinib and acetaminophen in a preclinical mouse model.

  2010cites this paper
• Gastrointestinal toxicities of novel agents in cancer therapy.

  2009cites this paper
• Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)

  2008cites this paper
• Sunitinib‐Related Fulminant Hepatic Failure: Case Report and Review of the Literature

  2008cites this paper
• Experiencia en el tratamiento de la hipertensin arterial pulmonar con imatinib

  2008cites this paper
• [Experience with imatinib to treat pulmonary arterial hypertension].

  2008cites this paper
• Experience With Imatinib to Treat Pulmonary Arterial Hypertension

  2008cites this paper
• Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy

  2008cites this paper
• Dasatinib-induced acute hepatitis

  2008cites this paper
• Imatinib Mesylate (Gleevec) Hepatotoxicity

  2007influential citation
• Imatinib-induced fatal acute liver failure.

  2007cites this paper
• Hepatitis tóxica por imatinib: descripción de dos casos y revisión de la literatura médica

  2007cites this paper
• Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.

  2007cites this paper
• Cancer chemotherapy I: hepatocellular injury.

  2007cites this paper
• Successful Imatinib Treatment of Cardiac Involvement of FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia Followed by Severe Hepatotoxicity

  2007cites this paper
• [Imatinib-induced toxic hepatitis: description of two cases and review of the literature].

  2007cites this paper
• Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour.

  2006cites this paper
• Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase

  2006cites this paper
• Chapter 26 – Drug-Induced Liver Injury

  2006cites this paper
• Imatinib mesylate as a cause of acute liver failure

  2006cites this paper
• Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era.

  2006cites this paper
• Polycythemia vera: scientific advances and current practice.

  2005cites this paper
• A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats.

  2005cites this paper
• Severe Hepatic Injury Caused by Imatinib Mesylate Administered for the Treatment of Chronic Myeloid Leukemia and the Efficacy of Prednisolone for its Management

  2005cites this paper
• Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.

  2004cites this paper